Home>>Signaling Pathways>> DNA Damage/DNA Repair>> CDK>>PD 0332991 (Palbociclib) HCl

PD 0332991 (Palbociclib) HCl Sale

(Synonyms: 帕布昔利布盐酸盐,PD0332991;PD-0332991;PD 0332991) 目录号 : GC17935

A selective cyclin D kinase 4/6 inhibitor

PD 0332991 (Palbociclib) HCl Chemical Structure

Cas No.:827022-32-2

规格 价格 库存 购买数量
10mM (in 1mL DMSO)
¥620.00
现货
5mg
¥389.00
现货
25mg
¥683.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

实验参考方法

Cell experiment [1]:

Cell lines

Human ESCC cell lines EC109 and EC9706 cells

Preparation Method

Cellular senescence was assayed by measuring senescence‐associated β‐galactosidase (SA‐β‐gal) activity. Cells were grown in 6‐well flat‐bottom plates for 24 h and then treated without or with 2.5 μM PD‐0332991 for 6 days.

Reaction Conditions

2.5 μM; for 6 days

Applications

Treatment with PD‐0332991 drastically increased the activity of SA‐β‐gal, a marker for senescent cells in EC109 and EC9706 cells.

Animal experiment [2]:

Animal models

Female 6-week-old athymic nude mice (BALB/c Slc-nu/nu)

Preparation Method

In mice bearing human endometrial cancer, daily p.o. dosing for 21 days with PD-0332991 (50 or 150 ng/kg) suppressed tumor growth.

Dosage form

50 or 150 ng/kg; p.o.

Applications

The Ki67 index in the PD-0332991-treated group was significantly lower than that in the control group. Furthermore, the phospho-Rb expression of the PD-0332991-treated group was significantly lower than that in the control group.

References:

[1]. Chen L, et al. Dual cyclin-dependent kinase 4/6 inhibition by PD-0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells. Br J Pharmacol. 2017 Aug;174(15):2427-2443. 

[2]. Tanaka T, et al. The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer. PLoS One. 2017 May 4;12(5):e0177019. 

产品描述

PD 0332991, as an orally active potent and highly selective inhibitor of CDK4 and CDK6 kinases, can block pRb phosphorylation and subsequently inducing G1 arrest in sensitive cell lines in low nanomolar concentrations. [1][2]

In vitro, single treatment with 8 μmol/L or 16 μmol/L gefinitib inhibited PC-9 cell proliferation.[3] In vitro efficacy test it shown that PD-0332991 acted as a concentration-dependent inhibitor of cell proliferation with an IC50 of 0.65 and 0.58 μM, respectively, in HEC1A and HEC108 cells, however, PD-0332991 did not inhibit cell proliferation in ECC and TEN cells, even at concentrations of up to 1 μM.[4] PD-0332991 has G0/G1 cell-cycle arrest, induction of late apoptosis, and blockade of RB phosphorylation in RCC cell lines with IC50 values ranged from 25.0 nM to 700 nM. [5] PD 0332991 inhibited the AN, RY, G401 and NS cell lines with IC50 of 0.01 μM, 0.01 μM, 0.06 μM, and 0.6 μM, respectively. And PD 0332991 at 0 to 1.0 μM concentrations induced G1 arrest in the AN, RY, G401 and NS cell lines in a concentration-dependent manner, but had no effect on YM cells.[6]

In vivo, treatment with 150 mg/kg PD 0332991 and 100 mg/kg gefitinib inhibited tumor growth, all of the mice had a tumor volume < 30 mm3 after 14 days of treatment, and 20% (2/10) of the mice were completely cured without relapse.[3] In vivo, nu/nu BALB/c nude mice with EC109 cells s.c. were treated with 150 mg/kg orally PD‐0332991, the results shown that PD‐0332991 significantly inhibited the growth curve (tumour volume versus time curve) of EC109 tumours. And the tumour weight in the PD‐0332991‐treated mice was obviously lower than the vehicle‐treated mice.[7]

References:
[1]Fry DW, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.?Mol Cancer Ther.?2004;3:1427–1438.
[2]Saab R, et al. Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells.?Mol Cancer Ther.?2006;5:1299–1308. doi:?10.1158/1535-7163.MCT-05-0383.?
[3]Liu M, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors. Oncotarget. 2016 Dec 20;7(51):84951-84964.?
[4]Tanaka T, et al. The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer. PLoS One. 2017 May 4;12(5):e0177019.?
[5]Logan JE, et al. PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. Anticancer Res. 2013 Aug;33(8):2997-3004.
[6]Katsumi Y, et al. Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression. Biochem Biophys Res Commun. 2011 Sep 16;413(1):62-8.?
[7] Chen L, et al. Dual cyclin-dependent kinase 4/6 inhibition by PD-0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells. Br J Pharmacol. 2017 Aug;174(15):2427-2443.

PD 0332991 作为 CDK4 和 CDK6 激酶的口服活性强效和高选择性抑制剂,可以在低纳摩尔浓度下阻断 pRb 磷酸化并随后在敏感细胞系中诱导 G1 期停滞。 [1][2]

在体外,8 μmol/L或16 μmol/L吉非替尼单药处理可抑制PC-9细胞增殖。[3] 体外药效试验表明,PD-0332991作为浓度细胞增殖依赖性抑制剂,在 HEC1A 和 HEC108 细胞中的 IC50 分别为 0.65 和 0.58 μM,然而,PD-0332991 不抑制 ECC 和 TEN 细胞中的细胞增殖,即使在一定浓度下高达 1 μM。[4] PD-0332991 在 RCC 细胞系中具有 G0/G1 细胞周期停滞、诱导晚期细胞凋亡和阻断 RB 磷酸化,IC 为 50 值范围从 25.0 nM 到 700 nM。 [5] PD 0332991 抑制 AN、RY、G401 和 NS 细胞系,IC50 分别为 0.01 μM、0.01 μM、0.06 μM 和 0.6 μM。 0 至 1.0 μM 浓度的 PD 0332991 以浓度依赖性方式诱导 AN、RY、G401 和 NS 细胞系的 G1 期阻滞,但对 YM 细胞没有影响。[6]/ p>\n

在体内,用 150 mg/kg PD 0332991 和 100 mg/kg 吉非替尼治疗可抑制肿瘤生长,所有小鼠的肿瘤体积均为 <;治疗14天后30 mm3,20%(2/10)的小鼠完全治愈,无复发。[3]体内,nu/nu BALB/c裸鼠皮下EC109细胞口服 150 mg/kg PD-0332991,结果显示 PD-0332991 显着抑制 EC109 肿瘤的生长曲线(肿瘤体积与时间曲线)。并且 PD-0332991 处理的小鼠的肿瘤重量明显低于载体处理的小鼠。[7]

Chemical Properties

Cas No. 827022-32-2 SDF
别名 帕布昔利布盐酸盐,PD0332991;PD-0332991;PD 0332991
化学名 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one hydrochloride
Canonical SMILES O=C1N(C2=NC(NC3=NC=C(C=C3)N4CCNCC4)=NC=C2C(C)=C1C(C)=O)C5CCCC5.Cl
分子式 C24H30ClN7O2 分子量 483.99
溶解度 ≥ 2.4mg/mL in DMSO, ≥ 24.2mg/mL in Water, ≥ 2.79 mg/mL in EtOH with ultrasonic and warming 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 2.0662 mL 10.3308 mL 20.6616 mL
5 mM 0.4132 mL 2.0662 mL 4.1323 mL
10 mM 0.2066 mL 1.0331 mL 2.0662 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Breast Cancer Res2009;11(5):R77.PMID: 19874578DOI: 10.1186/bcr2419

Introduction: Alterations in cell cycle regulators have been implicated in human malignancies including breast cancer. PD 0332991 is an orally active, highly selective inhibitor of the cyclin D kinases (CDK)4 and CDK6 with ability to block retinoblastoma (Rb) phosphorylation in the low nanomolar range. To identify predictors of response, we determined the in vitro sensitivity to PD 0332991 across a panel of molecularly characterized human breast cancer cell lines.
Methods: Forty-seven human breast cancer and immortalized cell lines representing the known molecular subgroups of breast cancer were treated with PD 0332991 to determine IC50 values. These data were analyzed against baseline gene expression data to identify genes associated with PD 0332991 response.
Results: Cell lines representing luminal estrogen receptor-positive (ER+) subtype (including those that are HER2 amplified) were most sensitive to growth inhibition by PD 0332991 while nonluminal/basal subtypes were most resistant. Analysis of variance identified 450 differentially expressed genes between sensitive and resistant cells. pRb and cyclin D1 were elevated and CDKN2A (p16) was decreased in the most sensitive lines. Cell cycle analysis showed G0/G1 arrest in sensitive cell lines and Western blot analysis demonstrated that Rb phosphorylation is blocked in sensitive lines but not resistant lines. PD 0332991 was synergistic with tamoxifen and trastuzumab in ER+ and HER2-amplified cell lines, respectively. PD 0332991 enhanced sensitivity to tamoxifen in cell lines with conditioned resistance to ER blockade.
Conclusions: These studies suggest a role for CDK4/6 inhibition in some breast cancers and identify criteria for patient selection in clinical studies of PD 0332991

Palbociclib (PD-0332991) (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma

Gut2017 Jul;66(7):1286-1296.PMID: 27849562DOI: 10.1136/gutjnl-2016-312268

Objective: Advanced hepatocellular carcinoma (HCC) is a lethal malignancy with limited treatment options. Palbociclib, a well-tolerated and selective CDK4/6 inhibitor, has shown promising results in the treatment of retinoblastoma (RB1)-positive breast cancer. RB1 is rarely mutated in HCC, suggesting that Palbociclib could potentially be used for HCC therapy. Here, we provide a comprehensive characterisation of the efficacy of Palbociclib in multiple preclinical models of HCC.
Design: The effects of Palbociclib on cell proliferation, cellular senescence and cell death were investigated in a panel of human liver cancer cell lines, in ex vivo human HCC samples, in a genetically engineered mouse model of liver cancer, and in human HCC xenografts in vivo. The mechanisms of intrinsic and acquired resistance to Palbociclib were assessed in human liver cancer cell lines and human HCC samples by protein and gene expression analyses.
Results: Palbociclib suppressed cell proliferation in human liver cancer cell lines by promoting a reversible cell cycle arrest. Intrinsic and acquired resistance to Palbociclib was determined by loss of RB1. A signature of 'RB1 loss of function' was found in <30% of HCC samples. Palbociclib, alone or combined with sorafenib, the standard of care for HCC, impaired tumour growth in vivo and significantly increased survival.
Conclusions: Palbociclib shows encouraging results in preclinical models of HCC and represents a novel therapeutic strategy for HCC treatment, alone or particularly in combination with sorafenib. Palbociclib could potentially benefit patients with RB1-proficient tumours, which account for 70% of all patients with HCC.

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts

Mol Cancer Ther2004 Nov;3(11):1427-38.PMID: 15542782DOI: 10.1111/1759-7714.13866

PD 0332991 is a highly specific inhibitor of cyclin-dependent kinase 4 (Cdk4) (IC50, 0.011 micromol/L) and Cdk6 (IC50, 0.016 micromol/L), having no activity against a panel of 36 additional protein kinases. It is a potent antiproliferative agent against retinoblastoma (Rb)-positive tumor cells in vitro, inducing an exclusive G1 arrest, with a concomitant reduction of phospho-Ser780/Ser795 on the Rb protein. Oral administration of PD 0332991 to mice bearing the Colo-205 human colon carcinoma produces marked tumor regression. Therapeutic doses of PD 0332991 cause elimination of phospho-Rb and the proliferative marker Ki-67 in tumor tissue and down-regulation of genes under the transcriptional control of E2F. The results indicate that inhibition of Cdk4/6 alone is sufficient to cause tumor regression and a net reduction in tumor burden in some tumors.

PD-0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance

Thorac Cancer2021 Mar;12(6):924-931.PMID: 33534964DOI: 10.1111/1759-7714.13866

Background: Acquired resistance of chemotherapy, especially cisplatin, is a major challenge in lung cancer treatment. We conducted this study to examine whether a cyclin D kinase 4/6 (CDK4/6) inhibitor, PD 0332991, could reverse cisplatin resistance in human lung cancer cells. In addition, we explored the underlying mechanisms.
Method: We used CCK-8 assay to got the IC50 of PD-0332991 and cisplatin in A549 and A549/CDDP respectively. CCK-8 assay, CalcuSyn 2.0 software, cell cycle distribution and apoptosis used to identify PD-0332991 could reverse the acquired resistance of cisplatin. At last, western-blot used to show the mechanism of PD-0332991 enhances the effects of cisplatin.
Results: We found that PD-0332991 potentiated cisplatin-induced growth inhibition in both cisplatin-sensitive (A549) and cisplatin-resistant (A549/CDDP) cells via downregulation of the proliferation, induction of apoptosis (A549 increased to 7.06%; A549/CDDP increased to 7.03%), and G0/G1 cell cycle arrest (A549 increased to 9.15%; A549/CDDP increased to 49.92%). Western blot analysis revealed that PD-0332991 enhance the effect of cisplatin through inhibit Rb-E2Fs pathway.
Conclusions: These findings suggest that PD-0332991 could reverse the acquired resistance of cisplatin in lung cancer cells and provide a novel treatment strategy for lung cancer patients with cisplatin resistance.

Palbociclib (PD-0332991) pharmacokinetics in subjects with impaired renal function

Cancer Chemother Pharmacol2020 Dec;86(6):701-710.PMID: 33037918DOI: 10.1007/s00280-020-04163-4

Purpose: This publication describes an evaluation of the impact of different degrees of renal impairment on the pharmacokinetics and safety of Palbociclib after a single 125-mg oral dose.
Methods: Thirty-one subjects were assigned to different renal function groups. Serial blood sampling for pharmacokinetics was performed up to 120 h and 168 h post-Palbociclib dose for subjects with normal and impaired renal function, respectively. A separate blood sample was collected at pre-dose and 8 h after dosing to measure plasma protein binding. Plasma Palbociclib was measured using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. Plasma protein binding samples were processed by equilibrium dialysis and measured by a validated LC-MS/MS method.
Results: Plasma Palbociclib exposure was higher in subjects with renal impairment than in subjects with normal renal function; however, there were no marked differences in exposure across subjects with mild, moderate, and severe renal impairment. Total plasma exposure AUCinf increased by 39%, 42%, and 31% with mild, moderate, and severe renal impairment, respectively, relative to subjects with normal renal function. Peak exposure Cmax increased by 17%, 12%, and 15% for mild, moderate, and severe impairment, respectively. There was no obvious trend in the mean fu with worsening renal function. The PBPK model adequately described Palbociclib exposure observed in subjects with moderate or severe renal impairment from this study.
Conclusion: Palbociclib was safe and well-tolerated in a small population of subjects with normal and impaired renal function after a single oral 125 mg dose. No dose adjustment is required in patients with renal impairment.